Is Spinraza worth $750K? Biogen says yes, spelling out reduced death risk
Biogen took a lot of analysts by surprise recently when the big biotech announced that its breakthrough drug for spinal muscular atrophy would be priced at $750,000 for the first year, and $375,000 for each subsequent year. But investigators just spelled out the data from their pivotal study, demonstrating a clear reduction in the risk of death.
While the study was stopped early due to its success, 68% of the untreated infants in the study either died or required permanent ventilation compared to 39% of the drug arm. That represented a 47% drop in the risk of death or need for permanent ventilation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
